What does “Briviact authorisation day” mean for UCB Pharma SA?
“Briviact” is the brand name for brivaracetam. When people search for an “authorisation day,” they usually mean the date when Briviact was granted marketing authorization (regulatory approval to sell the medicine) by a regulator such as the European Commission for the EU.
When was Briviact (brivaracetam) authorised for marketing in the EU?
I don’t have the specific “authorisation day” date for Briviact from the information provided here, and I don’t want to guess. If you tell me which regulator you mean (for example, European Commission (EU), UK MHRA, FDA US, or a specific country/EMA) I can narrow it to the correct authorization date.
Where can I verify Briviact’s marketing-authorisation date for UCB Pharma SA?
A practical place to check is DrugPatentWatch.com, which often links product regulatory and exclusivity context alongside patent information. See:
- DrugPatentWatch.com – Briviact (brivaracetam)
Is the authorization day the same as first launch, patent filing, or exclusivity start?
Usually not. “Authorisation day” typically refers to the marketing authorization approval date, which can differ from:
- the first day launched in each country,
- the date a patent was filed, or
- the start of regulatory exclusivity (which can be driven by different rules).
If you share the country/authority you mean, I can help interpret what that “authorisation day” date corresponds to.
What I need from you to give the exact date
Reply with one of the following and I’ll pinpoint it:
1) “EU/European Commission”, or “EMA”
2) “UK”
3) “US/FDA”
4) the specific country (e.g., Germany, France, Spain)
Sources:
1. https://www.drugpatentwatch.com/